Look for shake-ups in the business of health in 2019. Insurers, providers, and other business interests are working together to fundamentally change the way healthcare is delivered.

Diet and other health tracking mobile applications have become a part of everyday life for many people, and patients with kidney disease are no exception. Patients can choose from numerous kidney nutrition apps available in app stores, but experts warn many contain misleading or inaccurate information and few have undergone rigorous testing to ensure they are safe and effective.

Our top area to watch for 2019 is the advent of sodium glucose cotransporter 2 (SGLT2) inhibitors, oral anti-hyperglycemic agents that have been recently approved for the treatment of type 2 diabetes mellitus (T2DM).

Despite the substantial successes of kidney transplantation, this field continues to be hampered by the inability to monitor the intensity of the immunosuppressive regimens. As a result, chronic antibody-mediated rejection (under-immunosuppression), as well as drug-related toxicity, malignancies, and opportunistic infections (over-immunosuppression) continue to be the leading causes of allograft loss.

The addition of anti-inflammatory and immunosuppressive drugs to the standard of care (SOC) treatment of systemic autoimmune disorders affecting the kidney has impressively improved outcomes over the past decades.